Uric acid: a novel mediator and marker of risk in chronic kidney disease?
Uric acid: a novel mediator and marker of risk in chronic kidney disease?
复制标题
DOI：
10.1097/mnh.0b013e328330d9d0
复制
发表时间：
2009-11
影响因子：
3.2
通讯作者：
Feig DI
中科院分区：
文献类型：
--
作者：
Feig DI
评估当前数据表明降尿酸疗法可能有助于预防或减轻慢性肾脏疾病（CKD）。在过去的两年中，已经发表了11项观察性研究，评估血清尿酸在CKD患病率和进展中的潜在作用。7个建议联想，4个不建议联想。最近的实验模型和临床试验表明血清尿酸和高血压（CKD的一个确定的危险因素）有机制联系。血清尿酸升高是肾功能下降的标志，可能在肾功能下降的发生和进展中起机制作用，并可能在高血压和血管疾病中起因果作用。需要临床试验来确定降尿酸疗法是否能有效预防慢性肾病。
To assess the current data suggesting that uric acid lowering therapy may be useful in the prevention or mitigation of chronic kidney disease (CKD). Eleven observational studies assessing the potential role of serum uric acid in the prevalence and progression of CKD have been published in the last 2 years. Seven suggest an association, 4 do not. Recent experimental models and clinical trials have mechanistically linked serum uric acid and hypertension, an established risk factor for CKD. Elevated serum uric acid is a marker for decreased renal function, may have a mechanistic role in the incidence and progression of renal functional decline and likely has a causal role in hypertension and vascular disease. Clinical trials are needed to determine if uric acid lowering therapy will be effective in preventing CKD.